HIV-hepatitis C coinfection: Difference between revisions

From IDWiki
No edit summary
()
Line 9: Line 9:
* Consult [https://www.hep-druginteractions.org/checker HEP Drug Interactions checker]
* Consult [https://www.hep-druginteractions.org/checker HEP Drug Interactions checker]
* Be careful with Harvoni, which can increase levels of tenofovir, especially when GFR <60 mL/min
* Be careful with Harvoni, which can increase levels of tenofovir, especially when GFR <60 mL/min

{| class="wikitable"
! !! !! LDV/SOF !! SOF/VEL !! ELB/GRZ !! GLE/PIB !! SOF/VEL/VOX
|-
| rowspan = 3 | PI
| [[ATV/r]]
| style="background:yellow" | A
| style="background:yellow" | A
| style="background:red" |
| style="background:red" |
| style="background:red" |
|-
| [[DRV/r]]
| style="background:yellow" | A
| style="background:yellow" | A
| style="background:red" |
| style="background:red" |
| style="background:yellow" |
|-
| [[LPR/r]]
| style="background:yellow" | A,ND
| style="background:yellow" | A
| style="background:red" |
| style="background:red" |
| style="background:red" | ND
|-
| rowspan=4 | NNRTI
| [[DOR]]
| style="background:green" |
| style="background:green" | ND
| style="background:green" |
| style="background:green" | ND
| style="background:green" | ND
|-
| [[EFZ]]
| style="background:green" |
| style="background:red" |
| style="background:red" |
| style="background:red" | ND
| style="background:red" | ND
|-
| [[RPV]]
| style="background:green" |
| style="background:green" |
| style="background:green" |
| style="background:green" |
| style="background:green" |
|-
| [[ETR]]
| style="background:green" | ND
| style="background:red" | ND
| style="background:red" | ND
| style="background:red" | ND
| style="background:red" | ND
|-
| rowspan=4 | INSTI
| [[BIC]]
| style="background:green" |
| style="background:green" | ND
| style="background:green" | ND
| style="background:green" | ND
| style="background:green" |
|-
| [[EVG/c]]
| style="background:yellow" | C
| style="background:yellow" | C
| style="background:red" |
| style="background:yellow" |
| style="background:yellow" | C
|-
| [[EVG/r]]
| style="background:green" |
| style="background:green" |
| style="background:green" |
| style="background:green" |
| style="background:green" | ND
|-
| [[RTG]]
| style="background:green" |
| style="background:green" |
| style="background:green" |
| style="background:green" |
| style="background:green" | ND
|-
| EI
| [[MVC]]
| style="background:green" | ND
| style="background:green" | ND
| style="background:green" | ND
| style="background:green" | ND
| style="background:green" | ND
|-
| rowspan=5 | NRTI
| [[ABC]]
| style="background:green" |
| style="background:green" | ND
| style="background:green" | ND
| style="background:green" |
| style="background:green" | ND
|-
| [[FTC]]
| style="background:green" |
| style="background:green" |
| style="background:green" |
| style="background:green" |
| style="background:green" |
|-
| [[3TC]]
| style="background:green" |
| style="background:green" | ND
| style="background:green" | ND
| style="background:green" |
| style="background:green" | ND
|-
| [[TDF]]
| style="background:yellow" | B,C
| style="background:yellow" | B,C
| style="background:green" |
| style="background:green" |
| style="background:yellow" | C,D
|-
| [[TAF]]
| style="background:green" | D
| style="background:green" | D
| style="background:green" | ND
| style="background:green" |
| style="background:green" | D
|}

* '''Green''' = safe; '''yellow''' = dose change or close monitoring; '''red''' = avoid
* '''ND''' = no data; '''A''' = caution with TDF only; '''B''' = increase in tenofovir possible; '''C''' = avoid TDF with eGFR < 60 mL/min; '''D''' = studied in fixed-dose combinations only


== Further Reading ==
== Further Reading ==

Revision as of 14:36, 16 July 2020

Principles

  • Confirm both diagnoses, including ensuring HCV RNA is still positive 6 months after first measured
  • Treat the HIV first, using any first-line regimen
  • Treat the HIV for at least 2 weeks before starting HCV treatment

Regimens

LDV/SOF SOF/VEL ELB/GRZ GLE/PIB SOF/VEL/VOX
PI ATV/r A A
DRV/r A A
LPR/r A,ND A ND
NNRTI DOR ND ND ND
EFZ ND ND
RPV
ETR ND ND ND ND ND
INSTI BIC ND ND ND
EVG/c C C C
EVG/r ND
RTG ND
EI MVC ND ND ND ND ND
NRTI ABC ND ND ND
FTC
3TC ND ND ND
TDF B,C B,C C,D
TAF D D ND D
  • Green = safe; yellow = dose change or close monitoring; red = avoid
  • ND = no data; A = caution with TDF only; B = increase in tenofovir possible; C = avoid TDF with eGFR < 60 mL/min; D = studied in fixed-dose combinations only

Further Reading